Operating costs and other operating income - Impairment of the cell therapy business (Details) - EUR (€) |
12 Months Ended | |
|---|---|---|
Sep. 30, 2025 |
Dec. 31, 2025 |
|
| Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
| Impairment loss | € 228,112,000 | |
| Full impairment of goodwill | 69,404,000 | |
| Cell Therapy Business Associated Assets [member] | ||
| Disclosure of information for impairment loss recognised or reversed for individual asset or cash-generating unit [line items] | ||
| Impairment loss | 228,100,000 | |
| Full impairment of goodwill | 69,400,000 | |
| Full impairment of intangible assets | € 132,000,000 | 132,000,000 |
| Partial impairment of property, plant and equipment | € 26,700,000 |